Found 30 matching trials
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. MenactraĀ® in Healthy Adolescent/Adults Aged 10-25 Years. PHASE2 The purpose of the study is to characterize the safety and immunogenicity o...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax⢠in 2-10 Year Old Subjects PHASE3 The purpose of this study is to demonstrate, in 2-10 year old subjects, the...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old PHASE2 The purpose of this study is to evaluate the immunogenicity, safety and rea...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix⢠to 18-55 Year-Old Adults PHASE3 The purpose of this study is to demonstrate, in 18-55 year old adults, the ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus MenactraĀ® in Healthy Adolescents/Adults PHASE2 The purpose of this observer-blind study is to evaluate the safety and immu...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children PHASE3 The purpose of the study is to evaluate the persistence of the immune respo...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A PHASE3 The purpose of this trial is to assess if the rate of febrile reactions fol...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects PHASE2 In this study, subjects who were vaccinated with a meningococcal polysaccha...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13ā¢Vaccine PHASE3 The purpose of this study is to compare the immediate and long term (up to ...
Show More Location
Canberra Hospital
Learn More & Join Trial
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration PHASE3 The purpose of this study is to demonstrate, in 12-23 months old subjects, ...
Show More Location
GSK Investigational Site
Learn More & Join Trial